The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring

• Published in: Internal Medicine Vol. 57; no. 17; pp. 2527 - 2531
• Main Authors: Yanagiya, Shingo, Cho, Kyu Yong, Nakamura, Akinobu, Nomoto, Hiroshi, Kawamoto, Yasuyuki, Kawakubo, Kazumichi, Komatsu, Yoshito, Mitsuhashi, Tomoko, Miyoshi, Hideaki, Atsumi, Tatsuya
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.09.2018; Japan Science and Technology Agency
• Subjects: Aged, 80 and over; Antineoplastic Agents - therapeutic use; Blood Glucose - drug effects; Blood Glucose Self-Monitoring; Case Report; continuous glucose monitoring; everolimus; Everolimus - therapeutic use; Female; Glucose; Glucose monitoring; Hematologic Tests; Humans; Hypoglycemia; Hypoglycemia - drug therapy; Insulinoma; Insulinoma - drug therapy; Insulinoma - pathology; Internal medicine; Metastases; Metastasis; Neoplasm Metastasis; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; continuous glucose monitoring; everolimus; hypoglycemia
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.0126-17

An 84-year-old Japanese woman with metastatic insulinoma suffered from frequent hypoglycemic events. Continuous glucose monitoring (CGM) confirmed severe and frequent symptomatic/asymptomatic hypoglycemia. After the initiation of everolimus treatment, the hypoglycemic events were rapidly eliminated. CGM revealed that her blood glucose levels were maintained without hypoglycemia throughout the day. Furthermore, everolimus reduced the duration of time above the upper limit (>180 mg/dL) along with the standard deviation and mean amplitude of glycemic excursions. This case shows the potential effects of everolimus on hypoglycemia and glycemic control in a patient with inoperable metastatic insulinoma evaluated by CGM.